Peptide delivery - Oral delivery of peptides by peptelligence technology

Drug Development and Delivery

Volumn 13, Issue 2, 2013, Pages

  Stern, William ^a   Mehta, Nozer ^b,c   Carl, Stephen M ^a  

^a Unigene Laboratories Incorporated   (United States)

^b UNIVERSITY OF MUMBAI   (India)

^c UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CR 845; KAPPA OPIATE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ARTICLE; CELL TRANSPORT; DRUG COATING; DRUG DELIVERY SYSTEM; ENZYME DEGRADATION; EPITHELIUM CELL; STOMACH PH;

EID: 84875171702     PISSN: 15372898     EISSN: 1944818X     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (10)

1. Cara Therapeutics Successfully Completes Phase I Study With Oral Formulation of Its Novel Kappa Opioid Receptor Agonist, CR845. Website: http://www.caratherapeutics.com/cr845-phase1-complete-release.shtml.
2. Mehta N, Karsdal M, Tavakkol R, Stern W, Sturmer A, Mitta S, Henriksen K, Andersen J, Riis B, Alexandersen P, Valter I, Nedergaard B, Teglbjaerg C, Nino A, Fitzpatrick L, Christiansen C, Cosman F. A phase 2 randomized trial of orally administered PTH(1-31)NH2 tablets in postmenopausal women with osteoporosis. Paper presented at: ASBMR 2012 Annual Meeting, October 12-15, 2012, in Minneapolis, MN.
3. Henriksen K, Andersen JR, Riis BJ, Mehta N, Tavakkol R, Alexandersen P, Valter I, Nedergaard BS, Teglbjærg CS, Stern W, Sturmer A, Mitta S, Nino AJ, Fitzpatrick LA, Christiansen C, Karsdal MA. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH2] in postmenopausal women with osteoporosis. Bone. 2012 Dec 9. doi:pii: S8756-3282(12)01408-1. 10.1016/j.bone.2012.11.045. [Epub ahead of print].
4. Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, Buben CE, Gilligan JP, Krause DS. Oral calcitonin in postmenopausal osteoporosis (ORACAL) investigators: a phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the oral calcitonin in postmenopausal osteoporosis (ORACAL) trial. J Bone Miner Res. 2012;27(8):1821-1829.
5. Binkley N, Bone H, Bolognese M, Krause D. Safety and efficacy of orally administered recombinant salmon calcitonin tablets in the prevention of postmenopausal osteoporosis in women with low bone mass: a phase 2 placebo-controlled trial. Paper presented at: ASBMR 2012 Annual Meeting, October 12-15, 2012, in Minneapolis, MN.
6. Stern W, Gilligan J. Unigene Laboratories, Inc. (1999). Oral Salmon Calcitonin Pharmaceutical Products. US Patent No. 5,912,014.
7. Sinko PJ, Lee YH, Makhey V, Leesman GD, Sutyak JP, Yu H, Perry B, Smith CL, Hu P, Wagner EJ, Falzone LM, McWhorter LT, Gilligan JP, Stern W. Biopharmaceutical approaches for developing and assessing oral peptide delivery strategies and systems: in vitro permeability and in vivo oral absorption of salmon calcitonin (sCT). Pharm Res. 1999;16(4):527-533.
8. Lee YH, Perry BA, Labruno S, Lee HS, Stern W, Falzone LM, Sinko PJ. Impact of regional intestinal pH modulation on absorption of peptide drugs: oral absorption studies of salmon calcitonin in beagle dogs. Pharm Res. 1999;16(8):1233-1239.
9. Mehta N, Tavakkol R, Erickson K, Stern B, Gilligan J, Fein S, Mitta S, Sturmer A, Shields P, Rasums A, Fitzpatrick L. Clinical development of an orally delivered recombinant PTH analog. Paper presented at: ASBMR 2011 Annual Meeting, September 16-20, 2011, in San Diego, CA.
10. Sturmer A, Stern W, Giacchi J, Bolat A, Mitta S, Tavakkol R, Trang J, Wald J, Fitzpatrick L, Mehta N. Pharmacokinetic results of a phase 2 clinical study of an oral tablet formulation of PTH(1-31)NH2. Poster presented at: ASBMR 2012 Annual Meeting, October 12-15, 2012, in Minneapolis, MN.